3 results
8-K
EX-99.1
GUTS
Fractyl Health Inc.
13 May 24
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
4:01pm
in Germany that was initiated in the first quarter of 2023.
R&D Expenses: Research and development expense was $14.4 million for the quarter ended March 31
8-K
EX-99.1
GUTS
Fractyl Health Inc.
1 Apr 24
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:10am
for the year ended December 31, 2023.
R&D Expenses: Research and development expense was $10.2 million for the quarter ended December 31, 2023, compared
S-1/A
EX-10.9
GUTS
Fractyl Health Inc.
29 Jan 24
IPO registration (amended)
6:09am
selection (individually/combinatorially) and mechanistic explication of Rejuva candidates in R&D
Strategically guide and participate in engagement
- Prev
- 1
- Next